351 related articles for article (PubMed ID: 17576119)
1. Sequential analysis of latent variables using mixed-effect latent variable models: Impact of non-informative and informative missing data.
Sébille V; Hardouin JB; Mesbah M
Stat Med; 2007 Nov; 26(27):4889-904. PubMed ID: 17576119
[TBL] [Abstract][Full Text] [Related]
2. Impact of a mis-specification of the response rate under standard treatment in sequential clinical trials.
Sébille V; Bellissant E
Fundam Clin Pharmacol; 2005 Oct; 19(5):569-78. PubMed ID: 16176336
[TBL] [Abstract][Full Text] [Related]
3. Sequential boundaries approach in clinical trials with unequal allocation ratios.
Jafari P; Ayatollahi SM; Behboodian J
BMC Med Res Methodol; 2006 Jan; 6():1. PubMed ID: 16412232
[TBL] [Abstract][Full Text] [Related]
4. Sample size calculation for the Power Model for dose proportionality studies.
Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
[TBL] [Abstract][Full Text] [Related]
5. A latent-class mixture model for incomplete longitudinal Gaussian data.
Beunckens C; Molenberghs G; Verbeke G; Mallinckrodt C
Biometrics; 2008 Mar; 64(1):96-105. PubMed ID: 17608789
[TBL] [Abstract][Full Text] [Related]
6. The use of bootstrap methods for estimating sample size and analysing health-related quality of life outcomes.
Walters SJ; Campbell MJ
Stat Med; 2005 Apr; 24(7):1075-102. PubMed ID: 15570625
[TBL] [Abstract][Full Text] [Related]
7. Multiple imputation for model checking: completed-data plots with missing and latent data.
Gelman A; Van Mechelen I; Verbeke G; Heitjan DF; Meulders M
Biometrics; 2005 Mar; 61(1):74-85. PubMed ID: 15737080
[TBL] [Abstract][Full Text] [Related]
8. [Design and analysis of phase II trials in oncology with a group sequential method, the triangular test].
Bellissant E; Bénichou J; Chastang C
Therapie; 1991; 46(1):21-7. PubMed ID: 2020920
[TBL] [Abstract][Full Text] [Related]
9. The reassessment of trial perspectives from interim data--a critical view.
Bauer P; Koenig F
Stat Med; 2006 Jan; 25(1):23-36. PubMed ID: 16220517
[TBL] [Abstract][Full Text] [Related]
10. Sample size determination for assessing equivalence based on proportion ratio under a randomized trial with non-compliance and missing outcomes.
Lui KJ; Chang KC
Stat Med; 2008 Jan; 27(1):47-67. PubMed ID: 17708514
[TBL] [Abstract][Full Text] [Related]
11. Analysis of matched case-control data in presence of nonignorable missing exposure.
Sinha S; Maiti T
Biometrics; 2008 Mar; 64(1):106-14. PubMed ID: 17573865
[TBL] [Abstract][Full Text] [Related]
12. Likelihood methods for regression models with expensive variables missing by design.
Zhao Y; Lawless JF; McLeish DL
Biom J; 2009 Feb; 51(1):123-36. PubMed ID: 19197954
[TBL] [Abstract][Full Text] [Related]
13. Sample size re-estimation in group-sequential response-adaptive clinical trials.
Morgan CC
Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
[TBL] [Abstract][Full Text] [Related]
14. Power and sample size when multiple endpoints are considered.
Senn S; Bretz F
Pharm Stat; 2007; 6(3):161-70. PubMed ID: 17674404
[TBL] [Abstract][Full Text] [Related]
15. Simple adjustments for randomized trials with nonrandomly missing or censored outcomes arising from informative covariates.
Baker SG; Fitzmaurice GM; Freedman LS; Kramer BS
Biostatistics; 2006 Jan; 7(1):29-40. PubMed ID: 15923407
[TBL] [Abstract][Full Text] [Related]
16. Random effects and latent processes approaches for analyzing binary longitudinal data with missingness: a comparison of approaches using opiate clinical trial data.
Albert PS; Follmann DA
Stat Methods Med Res; 2007 Oct; 16(5):417-39. PubMed ID: 17656452
[TBL] [Abstract][Full Text] [Related]
17. [Roaming through methodology. XVI. What to do about missing data].
Stijnen T; Arends LR
Ned Tijdschr Geneeskd; 1999 Oct; 143(40):1996-2000. PubMed ID: 10535056
[TBL] [Abstract][Full Text] [Related]
18. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
Lachin JM
Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
[TBL] [Abstract][Full Text] [Related]
19. A bias correction in testing treatment efficacy under informative dropout in clinical trials.
Kong F; Chen YF; Jin K
J Biopharm Stat; 2009 Nov; 19(6):980-1000. PubMed ID: 20183460
[TBL] [Abstract][Full Text] [Related]
20. Analysis of change in the presence of informative censoring: application to a longitudinal clinical trial of progressive renal disease.
Schluchter MD; Greene T; Beck GJ
Stat Med; 2001 Apr; 20(7):989-1007. PubMed ID: 11276031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
